Literature DB >> 22301368

Comparison of biolimus eluted from an erodible stent coating with bare metal stents in acute ST-elevation myocardial infarction (COMFORTABLE AMI trial): rationale and design.

Lorenz Räber1, Henning Kelbaek, Miodrag Ostoijc, Andreas Baumbach, David Tüller, Clemens von Birgelen, Marco Roffi, Giovanni Pedrazzini, Ran Kornowski, Klaus Weber, Dik Heg, Christian Matter, Thomas Lüscher, Masanori Taniwaki, Bernhard Meier, Peter Jüni, Stephan Windecker.   

Abstract

AIMS: Compared with bare metal stents (BMS), early generation drug-eluting stents (DES) reduce the risk of revascularisation in patients with ST-elevation myocardial infarction (STEMI) at the expense of an increased risk of very late stent thrombosis (ST). Durable polymer coatings for controlled drug release have been identified as a potential trigger for these late adverse events and this has led to the development of newer generation DES with durable and biodegradable polymer surface coatings with improved biocompatibility. In a recent all-comers trial, biolimus-eluting stents with a biodegradable polymer surface coating were found to reduce the risk of very late ST by 80% compared with sirolimus-eluting stents with durable polymer, which also translated into a lower risk of cardiac death and myocardial infarction (MI) beyond one year. METHODS AND
RESULTS: The multicentre COMFORTABLE AMI trial (NCT00962416) randomly assigned 1,161 patients to treatment with biolimus-eluting stents with biodegrable polymer and bare metal stents of otherwise identical design at 11 international sites. The primary endpoint is a composite of cardiac death, target-vessel MI and target lesion revascularisation at one year. Assuming a relative risk reduction of 40% in event rates of the primary endpoint in favour of biolimus-eluting stents with biodegradable polymer, 1,064 patients will provide 80% power to demonstrate superiority. Clinical follow-up will be continued through five years.
CONCLUSIONS: The COMFORTABLE AMI trial will determine whether biolimus-eluting stents with biodegradable polymer are superior to bare metal stents of otherwise identical design. This is the first randomised controlled trial (RCT) investigating DES with a biodegradable polymer surface coating for drug release in the treatment of patients with STEMI.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22301368     DOI: 10.4244/EIJV7I12A224

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  5 in total

1.  Long-term safety and feasibility of three-vessel multimodality intravascular imaging in patients with ST-elevation myocardial infarction: the IBIS-4 (integrated biomarker and imaging study) substudy.

Authors:  Masanori Taniwaki; Maria D Radu; Hector M Garcia-Garcia; Dik Heg; Henning Kelbæk; Lene Holmvang; Aris Moschovitis; Stephane Noble; Giovanni Pedrazzini; Kari Saunamäki; Jouke Dijkstra; Ulf Landmesser; Peter Wenaweser; Bernhard Meier; Giulio G Stefanini; Marco Roffi; Thomas F Lüscher; Stephan Windecker; Lorenz Räber
Journal:  Int J Cardiovasc Imaging       Date:  2015-02-28       Impact factor: 2.357

2.  Rehospitalizations Following Primary Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction: Results From a Multi-Center Randomized Trial.

Authors:  Ernest Spitzer; Martina Frei; Serge Zaugg; Susanne Hadorn; Henning Kelbaek; Miodrag Ostojic; Andreas Baumbach; David Tüller; Marco Roffi; Thomas Engstrom; Giovanni Pedrazzini; Vladan Vukcevic; Michael Magro; Ran Kornowski; Thomas F Lüscher; Clemens von Birgelen; Dik Heg; Stephan Windecker; Lorenz Räber
Journal:  J Am Heart Assoc       Date:  2017-08-05       Impact factor: 5.501

Review 3.  Drug-eluting stents versus bare-metal stents for acute coronary syndrome.

Authors:  Joshua Feinberg; Emil Eik Nielsen; Janette Greenhalgh; Juliet Hounsome; Naqash J Sethi; Sanam Safi; Christian Gluud; Janus C Jakobsen
Journal:  Cochrane Database Syst Rev       Date:  2017-08-23

4.  Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial.

Authors:  Joo Myung Lee; Ji-Hyun Jung; Kyung Woo Park; Eun-Seok Shin; Seok Kyu Oh; Jang-Whan Bae; Jay Young Rhew; Namho Lee; Dong-Bin Kim; Ung Kim; Jung-Kyu Han; Sang Eun Lee; Han-Mo Yang; Hyun-Jae Kang; Bon-Kwon Koo; Sanghyun Kim; Yun Kyeong Cho; Won-Yong Shin; Young-Hyo Lim; Seung-Woon Rha; Seok-Yeon Kim; Sung Yun Lee; Young-Dae Kim; In-Ho Chae; Kwang Soo Cha; Hyo-Soo Kim
Journal:  Trials       Date:  2015-09-15       Impact factor: 2.279

5.  Discordance in the diagnostic assessment of vulnerable plaques between radiofrequency intravascular ultrasound versus optical coherence tomography among patients with acute myocardial infarction: insights from the IBIS-4 study.

Authors:  Yasushi Ueki; Kyohei Yamaji; Sylvain Losdat; Alexios Karagiannis; Masanori Taniwaki; Marco Roffi; Tatsuhiko Otsuka; Konstantinos C Koskinas; Lene Holmvang; Rafaela Maldonado; Giovanni Pedrazzini; Maria D Radu; Jouke Dijkstra; Stephan Windecker; Hector M Garcia-Garcia; Lorenz Räber
Journal:  Int J Cardiovasc Imaging       Date:  2021-07-08       Impact factor: 2.357

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.